Moreover, CP-690,550 also prevented the activation of STAT1, induction of T-bet, and subsequent generation of Th1 cells. In a model of established arthritis, CP-690,550 rapidly improved disease by inhibiting the production of inflammatory mediators and suppressing STAT1-dependent genes in joint ...
Jaquinus, Xeljanz, tofacitinib (CP-690,550, CP-690550, tasocitinib) - BioCentury Product Profiles for the biopharma industry
2010年3月30---31两日,来自辉瑞公司美国总部的亚洲临床研究质量保证负责人Helen Q MD、RAIN MD等对正在风湿免疫科进行的国际多中心注册实验——“CP690,550治疗中重度类风湿关节炎的安全性和有效性3期临床试验”进行了质量检查。做为中国入组第一,全球入组第三的中心注册实验,试验负责人刘毅主任积极组织科室配合...
Tasocitinib-CP690550 最新更新日期:2025-01-14 14:36 CAS NO.:477600-75-2 联系人:肖小姐 联系电话: 13417589054 我要询单 QQ交流 查看化合物物化属性、结构、厂家等信息,点击:477600-75-2 深圳爱拓化学有限公司 VIP会员 地址:广东深圳宝安西乡华丰第一科技园汇庭居汇吉阁302 邮编:518126 手机:13417589054 ...
BackgroundPsoriasis is a chronic, inflammatory skin disease with a significant impact on health–related quality of life (HRQoL). Tofacitinib (CP-690,550) is a novel, oral Janus kinase inhibitor that is being investigated as a targeted immunomodulator.ObjectiveThis Phase 2b study assessed three tof...
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized ... Y Tanaka,SH Zwillich - 《Japanese Journal of Rheumatology》 被引量: 2发表: 2016年 AB0517THREE-YEAR SAFETY OF TOFACITINIB IN PATIENTS WITH ...
In the present study, CP-690,550 was utilized as an inhibitor of ex vivo proliferation of peripheral blood mononuclear cells (PBMCs) from patients with HTLV-I–associated ATL and HAM/TSP, in whom proliferation was inhibited by the addition of nanomolar concentrations of CP-690,550. These in...
Tofacitinib citrate(CP690550)抑制剂540737-29-9 订购说明由于产品太多无法一一上传!如需资料请联系客服! 上海羽朵生物优势供应国产/进口标准品,对照品,实验室常用试剂、elisa试剂盒、动物血清、血浆、全血、金标试剂盒、金标检测卡、生物试剂、培养基、实验室仪器耗材、化学试剂、生物制品。专业售后,贴心服务。 公司...
The Jak inhibitor CP-690,550 inhibits alloreactivity and is currently being investigated for prevention of allograft rejection after transplantation. In this study, we examined the effect of CP-690,550 on IL-2-mediated Jak/STAT5 phosphorylation by CD4+CD25brightFoxP3+CD127−/low T cells (...
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radi... ObjectiveThe purpose of this 24-month phase III study was to examine structural preservation with tofacitinib in patients with rheumatoid ...